What changed in Telix Pharmaceuticals Ltd's 2025 10-K compared to 2024?

Across the narrative sections we track, Telix Pharmaceuticals Ltd (TLX) added 0 paragraphs, removed 0, and edited 0 between the 2024 and 2025 10-K filings. The biggest movers are .

Where does this TLX 10-K diff come from?

The source filings are Telix Pharmaceuticals Ltd's official 2024 and 2025 Form 20-F annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

Telix Pharmaceuticals LtdTLX決算レポート

Nasdaq · ヘルスケア · 医薬製剤

Telix Pharmaceuticals Ltd is a global clinical-stage biopharmaceutical company specializing in the development and commercialization of targeted radiopharmaceutical products for oncology. Its core portfolio covers diagnostic imaging agents and therapeutic treatments for prostate, renal, and neuroendocrine cancers, serving markets across North America, Europe, and Asia-Pacific.

What changed in Telix Pharmaceuticals Ltd's 20-F — 2024 vs 2025

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.